Amifampridine

阿米吡啶

Report date: 2024/10/23 14:48:32
NME

Base Information

Drug NameAmifampridine
Drug Alias NameamifampridinumamifampridinaRuzurgi
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionVoltage-gated potassium channel blockers
TargetsVoltage-gated potassium channel
Therapy Area/IndicationsMultiple SclerosisLambert-Eaton Myasthenic SyndromeBotulism
Global Approved IndicationsMultiple SclerosisLambert-Eaton Myasthenic Syndrome
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2019/05/03
Country/TerritoryUnited StatesEU
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesJacobus
China Registration ClassN/A

Develop Information

Active CompaniesWake Forest University Health SciencesCatalyst Pharmaceuticals IncRontis Hellas Medical And Pharmaceutical Products Sa +[4] 
Inactive CompaniesN/A
Active IndicationsMultiple SclerosisLambert-Eaton Myasthenic SyndromeBotulism
Inactive IndicationsN/A

Other Information

ATC CodeN07XX05
Related LinksWikipediaDrugBankKEGG